呂海濤(上海交通大學系統生物醫學研究院研究員)

呂海濤博士，上海交通大學系統生物醫學研究院 研究員/課題組長/博導

基本介紹

• 中文名：呂海濤
• 外文名：Haitao Lu
• 國籍：中國
• 民族：漢族
• 出生地：黑龍江省
• 出生日期：1980-8-8
• 職業：研究員／博士生導師
• 畢業院校：黑龍江中醫藥大學
• 主要成就：精準修飾代謝組學，微生物代謝，中藥系統生物學

學習經歷
2004.09-2009.06 黑龍江中醫藥大學 藥學院 生藥學（碩博連讀） 博士學位
2000.09-2004.07 黑龍江中醫藥大學 藥學院 中藥學 學士學位

工作經歷

2016.09-至今 上海交通大學系統生物醫學研究院 研究員/課題組長/博導
2013.07-至今 QUT Vice Chancellor’s Fellowship (國際人才基金，Adjunct Faculty）
2012.09-2016.09 重慶大學藥學院（創新藥物研究中心）百人計畫研究員/博導/主任助理
2009.09-2013.01 美國愛因斯坦醫學院/華盛頓大學醫學院/麻省理工學院 博士後研究員

人才獎項

QUT校長特聘教授席人才基金
重慶大學百人計畫
上海交通大學特聘研究員

學會兼職與審稿人

中華中西醫結合學會中醫方證代謝組學分會副會長（籌）
世中聯網路藥理學專委會常務理事
中國藥理學會網路藥理學專委會理事
中國藥理學學會分析藥理學專委會創會理事
美國科學促進會（AAAS）榮譽會員
國際代謝組學學會會員
Phytomedicine (IF 3.6)副主編
Frontiers in Microbiology（IF 4.0）副主編
Frontiers in Pharmacology (IF 3.8) 副主編
Scientific Reports (IF 4.1) 編委
Bioanalysis (IF 2.65) 編委
Acta Pharmaceutica Sinica B (IF 6.0) 青年編委
Chinese Journal of Natural Medicines (IF 1.9) 青年編委

主持科研項目

1. 國家重點研發計畫; 胰腺癌轉移的階段化代謝特徵譜及代謝機理研究/ 2017YFC1308605；2017.06－2020.12; 獲批經費：334.0萬；主持人；在研

2. 國家自然科學基金面上項目；致病性大腸桿菌中新鐵載體的發現與功能表征/C010201； 2017.01-2020.12； 獲批經費：62.0萬； 主持人；在研

3. 國家自然科學基金面上項目；基於代謝組學技術表征中藥石韋治療尿路感染的活性組分和作用機制/81274175；2013.01-2016.12； 獲批經費：70.0萬；主持人；結題

4. 重慶自然基金面上項目；基於代謝組學技術表征中藥人參治療糖尿病的功能組分和作用機理/CSTC2014JCYIA10109；2014.09-2017.09；獲批經費：5.0萬；主持人；結題

5. 中央高校基本科研業務費學校創新重大項目；新鐵載體的發現與表征/ 2015CDJZR；2015.07-2017.07； 獲批經費：50.0萬；主持人；結題

6. 中央高校基本科研業務費跨學科重大項目；基於代謝組學技術的人參治療糖尿病的轉化醫學研究

/ CQDXWL-2014-Z002；2014.06-2017.06； 獲批經費：35.0萬； 主持人；在研

7. QUT Vice Chancellor's Research Fellowships（國際人才基金）；群體性肌肉損傷代謝生物標記物的發現與表征/ 150410-0070/08；2013.07-2016.07； 獲批經費：150.0萬；主持人；結題

　　

代表性論文

1. Luo, X., Guo, R., Xu, X., Li, X., Yao, L., Wang, X., and Lu, H*. (2018) Spectrometry And Associated Technologies Delineate The Advantageously Biomedical Capacity Of SiderophoresIn Different Pathogenic Contexts. Mass Spectrometry Reviews, doi: 10.1002/mas.21577(Invited by Editor in Chief)(*Corresponding Author)
   
2. Su, Q, Xu, G. Guan, T. Que, Y. and Lu, H*. (2018). Mass spectrometry-derived systems biology technologies delineate the system's applications of siderophores with chemistry and biology. Mass Spectrometry Reviews, 37, 188-201(Invited by Editor in Chief) (*Corresponding Author)
   
3. Su, Q., Guan, T. B., He, Y. and Lv, H*. (2016). Siderophore biosynthesis governs the virulence of uropathogenic Escherichia coli by coordinately modulating the differential metabolism. Journal of Proteome Research, 15, 1323-1332. (*Corresponding Author)
   
4. Nie, W.N., Yan, L. Y. Lee, Y. H., Guha, C., Kurland, I. J., and Lu, H.T.,* (2016).
   Advanced mass spectrometry based multiple omics technologies for exploring the
   pathogenesis of hepatocellular carcinoma. Mass Spectrometry Reviews, 35, 331-349. (*Corresponding Author)
   
5. Nie, W., Lv, Y., Yan, L., Chen, X. and Lv, H*. (2015): Prediction and Characterization of the System Effects of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological Mechanisms. Scientific Reports 5, 17646; doi: 10.1038/srep17646. (*Corresponding Author)
   
6. Lv, H. T*., Hung, C. S., and Henderson, J. P.* (2014): Metabolomic Analysis of Siderophore Cheater Mutants Reveals Metabolic Costs of Expression in Uropathogenic Escherichia coli. Journal of Proteome Research, 13, 1397-1404. (*Corresponding Author)
   
7. Lv, H. T.* (2013): Mass spectrometry based metabolomics towards understanding of gene functions with a diversity of biological contexts, Mass Spectrometry Reviews, 32, 118-128. (*Corresponding Author)
   
8. Lv, H.T., and Henderson, J. P. (2011): Yersinia High Pathogenicity Island genes modify the Escherichia coli primary metabolome independently of siderophore production. Journal Proteome Research, 10, 5547-5554.
   
9. Lv, H.T., Palacios, G., Hartil, K. and Kurland, I.J. (2011): Advantages of Tandem LC-MS for the Rapid Assessment of Tissue-specific Metabolic Complexity using a Pentafluorophenylpropyl Stationary Phase. Journal Proteome Research, 10, 2104-2012.
   
10. Lv, H.T*., Hung, C. S., Chaturvedi, K. S., Hooton, T. M., and Henderson, J.P.* (2011): Development of an integrated metabolomic approach for Infectious Diseases Research. Analyst, 136, 4752-4763. (*Corresponding Author)
    
11. Yan, L. Y., Nie, W. N., and Lv, H. T. * (2015) Metabolic Phenotyping of the Yersinia High-Pathogenicity Island that Regulates Central Carbon Metabolism. Analyst, 140, 3356-3361. (*Corresponding Author)
    
12. Lv, H.T*., Liu, L., Palacios, G. and Chen, X. (2011): Metabolomic Analysis Characterizes Tissue Specific Metabolic Perturbations of the Rats Induced by Indomethacin. Analyst, 136, 2260-2269. (*Corresponding Author)
    
13. Nie, W. N., Lv, Y. N., Yan, L. Y., Guan, T. B., Li, Q., Guo, X. J., Liu, W. H., Feng, M. P., Xu, G., Chen, X., Lv, H. T. * (2015) Discovery and Characterization of Disease Risk Functional Modules and Pathogenic Genes of Coronary Artery Disease. RSC Advances, 5, 26443-26451. (*Corresponding Author)
    
14. Lv, Y., Que, Y., Su, Q., Li, Q., and Lu, H*. (2016). Bioinformatics facilitating the use of microarrays to delineate potential miRNA biomarkers in aristolochic acid nephropathy. Oncotarget, doi: 10.18632/oncotarget.10586. (*Corresponding Author)
    
15. Su, Q., Guan, T. and Lv, H*. (2016) Siderophore biosynthesis coordinately modulated the virulence associated interactive metabolome of uropathogenic Escherichia coli and human urine. Scientific Reports, 6, 24099; doi: 10.1038/srep24099 (*Corresponding Author
    
16. Liu, W. H., Guo, X. J., Li, Q., Xu, G., Feng, M. P., Guan, T. B., Yan, L. Y., Nie, W. N., Parker, T., Lv, H. T. * Mass Spectrometry Based Molecular Profile Dissects The Complexity of Traditional Chinese Medicine. Anal Methods, 2015, 7, 2902-2912. (*Corresponding Author)
    
17. Wang, X.J*., Lv, H.T., Zhang, A. H., Wenjun Sun, Liu, L., Wang, P., Wu, Z.M., Zhou, D. X., Sun, H. * (2013) Metabolite profiling and pathway analysis of acute hepatitis rats by UPLC-ESI MS combined with pattern recognition methods. Liver International, 34, 759-770.
    
18. Wang. X.J.,* Zhang, A.H., Wang, P., Sun, H., Wu, G., Sun, W.J., Lv, H.T., et al. (2013): Metabolomics coupled with proteomics advancing drug discovery towards more agile development of targeted combination therapies. Mol Cell Proteomics. 12, 1226-1238.
    
19. Yan, L. Y., Nie, W.N., Parker, T., Upton, Z., Lv, H. T. * (2013) Mass spectrometry based metabolomics facilitates the discovery of in vivo functional small-molecules with a diversity of biological contexts. Future Medicinal Chemistry, 5, 1953-1965. (*corresponding author)